Pharmacokinetics of intranasal levetiracetam in healthy dogs: a feasible route of administration
American Journal of Veterinary Research · 2025
DOI: 10.2460/ajvr.25.10.0366 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Veterinary Research, 2025. Verfasst von Ewa Krolak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL. Hauptthemen laut MEDLINE: Levetiracetam, Anticonvulsants. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To describe the pharmacokinetics of the IV formulation of levetiracetam administered intranasally and calculate the absolute bioavailability. Our hypothesis was that levetiracetam would show near complete absorption following a single intranasal dose.
Methods
8 healthy dogs (4 female, 4 male) from a canine colony were used in a crossover study comparing the pharmacokinetics of intranasal and IV levetiracetam. The study occurred from August through September 2024. A 100-mg dose of levetiracetam was administered via the intranasal and IV routes on separate occasions. Blood was collected from jugular catheters over a 24-hour period following dose administration. Plasma levetiracetam concentrations were analyzed using high-pressure liquid chromatography. Noncompartmental analysis was performed to describe the pharmacokinetics.
Results
Median (minimum to maximum), maximal concentration, time to maximal concentration, and elimination half-life for the intranasal route were 7.85 µg/mL (range, 3.37 to 14.16), 0.98 hours (range, 0.22 to 1.00), and 2.83 hours (range, 2.44 to 3.76), respectively. Median (minimum to maximum) bioavailability was 61% (range, 34% to 85%). The maximal concentration achieved fell within the human reference interval for levetiracetam in 5 of 8 dogs.
Conclusions
Levetiracetam was absorbed to a moderate degree following the intranasal route of administration and appeared to be well tolerated. Clinical Relevance Levetiracetam is absorbed via the nasal administration route and could be considered a feasible route of administration for at-home rescue protocols. Although concentrations within the human reference interval were achieved in a majority of dogs, a clinical trial is necessary to determine if this method of administration would be effective in a clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL.
- Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL.
- Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL.
ORCID-Profile: Ewa Krolak, Kamoltip Thungrat, Amanda Gross, Katherine Gerken, Kendon Kuo, Tom Jukier
Zitieren
APA
Krolak, E., Thungrat, K., Gross, A., Gerken, K., Kuo, K., & Jukier, T. (2025). Pharmacokinetics of intranasal levetiracetam in healthy dogs: a feasible route of administration. American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.25.10.0366
Vancouver
Krolak E, Thungrat K, Gross A, Gerken K, Kuo K, Jukier T. Pharmacokinetics of intranasal levetiracetam in healthy dogs: a feasible route of administration. American Journal of Veterinary Research. 2025. doi:10.2460/ajvr.25.10.0366
BibTeX
@article{Krolak2025,
author = {Krolak, Ewa and Thungrat, Kamoltip and Gross, Amanda and Gerken, Katherine and Kuo, Kendon and Jukier, Tom},
title = {Pharmacokinetics of intranasal levetiracetam in healthy dogs: a feasible route of administration},
journal = {American Journal of Veterinary Research},
year = {2025},
doi = {10.2460/ajvr.25.10.0366}
}
EUVIMED